Edwards PASCAL System Shows Benefits in CLASP II TR Trial
Edwards Lifesciences announced that the CLASP II TR trial demonstrated superior clinical and quality-of-life benefits with its PASCAL system.
Story updates
06:25:20 PM UTC
SquawkNews
Edwards Lifesciences Corporation (NYSE:EW) today announced that the PASCAL system for tricuspid repair demonstrated superiority compared to medical therapy alone for the six-month primary endpoint of the CLASP II TR trial. The evidence further showed significant reduction of tricuspid regurgitation…